期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 75, 期 4, 页码 435-447出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.11.036
关键词
cardiorenal interaction; diabetes; heart failure; renal function; sodium-glucose cotransporter 2 inhibitor
资金
- German Research Foundation (Deutsche Forschungsgemeinschaft) [ZE 1109/1-1]
- AstraZeneca
- Daiichi-Sankyo
- GlaxoSmithKline
- Merck
- Novartis
Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research. (C) 2020 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据